Literature DB >> 11522598

Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice.

M El Yacoubi1, C Ledent, M Parmentier, R Bertorelli, E Ongini, J Costentin, J M Vaugeois.   

Abstract

1. Adenosine, an ubiquitous neuromodulator, and its analogues have been shown to produce 'depressant' effects in animal models believed to be relevant to depressive disorders, while adenosine receptor antagonists have been found to reverse adenosine-mediated 'depressant' effect. 2. We have designed studies to assess whether adenosine A2A receptor antagonists, or genetic inactivation of the receptor would be effective in established screening procedures, such as tail suspension and forced swim tests, which are predictive of clinical antidepressant activity. 3. Adenosine A2A receptor knockout mice were found to be less sensitive to 'depressant' challenges than their wildtype littermates. Consistently, the adenosine A2A receptor blockers SCH 58261 (1 - 10 mg kg(-1), i.p.) and KW 6002 (0.1 - 10 mg kg(-1), p.o.) reduced the total immobility time in the tail suspension test. 4. The efficacy of adenosine A2A receptor antagonists in reducing immobility time in the tail suspension test was confirmed and extended in two groups of mice. Specifically, SCH 58261 (1 - 10 mg kg(-1)) and ZM 241385 (15 - 60 mg kg(-1)) were effective in mice previously screened for having high immobility time, while SCH 58261 at 10 mg kg(-1) reduced immobility of mice that were selectively bred for their spontaneous 'helplessness' in this assay. 5. Additional experiments were carried out using the forced swim test. SCH 58261 at 10 mg kg(-1) reduced the immobility time by 61%, while KW 6002 decreased the total immobility time at the doses of 1 and 10 mg kg(-1) by 75 and 79%, respectively. 6. Administration of the dopamine D2 receptor antagonist haloperidol (50 - 200 microg kg(-1) i.p.) prevented the antidepressant-like effects elicited by SCH 58261 (10 mg kg(-1) i.p.) in forced swim test whereas it left unaltered its stimulant motor effects. 7. In conclusion, these data support the hypothesis that A2A receptor antagonists prolong escape-directed behaviour in two screening tests for antidepressants. Altogether the results support the hypothesis that blockade of the adenosine A2A receptor might be an interesting target for the development of effective antidepressant agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522598      PMCID: PMC1572930          DOI: 10.1038/sj.bjp.0704240

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  58 in total

Review 1.  The role of receptor structure in determining adenosine receptor activity.

Authors:  M E Olah; G L Stiles
Journal:  Pharmacol Ther       Date:  2000-02       Impact factor: 12.310

Review 2.  Animal models of depression: an overview.

Authors:  P Willner
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  Inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) mimics the effect of inescapable shock on escape learning in rats.

Authors:  J C Woodson; T R Minor; R F Job
Journal:  Behav Neurosci       Date:  1998-04       Impact factor: 1.912

Review 4.  Bupropion sustained release: a therapeutic overview.

Authors:  J R Davidson; K M Connor
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

5.  Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia.

Authors:  S H Kafka; R Corbett
Journal:  Eur J Pharmacol       Date:  1996-01-11       Impact factor: 4.432

6.  Evidence of dopamine involvement in the effect of repeated treatment with various antidepressants in the behavioural 'despair' test in rats.

Authors:  F Borsini; L Pulvirenti; R Samanin
Journal:  Eur J Pharmacol       Date:  1985-04-02       Impact factor: 4.432

Review 7.  Psychiatric applications of bromocriptine therapy.

Authors:  P A Sitland-Marken; B G Wells; J H Froemming; C C Chu; C S Brown
Journal:  J Clin Psychiatry       Date:  1990-02       Impact factor: 4.384

8.  [Polygraphic, clinical and therapeutic markers of dopamine-dependent depressions].

Authors:  J Mouret; P Lemoine; M P Minuit
Journal:  C R Acad Sci III       Date:  1987

9.  Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists.

Authors:  D Boulay; R Depoortere; G Perrault; E Borrelli; D J Sanger
Journal:  Neuropharmacology       Date:  1999-09       Impact factor: 5.250

10.  Long-term treatment with some methylxanthines decreases the susceptibility to bicuculline- and pentylenetetrazol-induced seizures in mice. Relationship to c-fos expression and receptor binding.

Authors:  B Johansson; V Georgiev; T Kuosmanen; B B Fredholm
Journal:  Eur J Neurosci       Date:  1996-12       Impact factor: 3.386

View more
  44 in total

1.  Impact of genetic variations in ADORA2A gene on depression and symptoms: a cross-sectional population-based study.

Authors:  Sílvia Oliveira; Ana Paula Ardais; Clarissa Ribeiro Bastos; Marta Gazal; Karen Jansen; Luciano de Mattos Souza; Ricardo Azevedo da Silva; Manuella Pinto Kaster; Diogo Rizzato Lara; Gabriele Ghisleni
Journal:  Purinergic Signal       Date:  2018-12-03       Impact factor: 3.765

Review 2.  Implication of the purinergic system in alcohol use disorders.

Authors:  Liana Asatryan; Hyung W Nam; Moonnoh R Lee; Mahesh M Thakkar; M Saeed Dar; Daryl L Davies; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2011-01-11       Impact factor: 3.455

3.  Behavioral profile assessment in offspring of Swiss mice treated during pregnancy and lactation with caffeine.

Authors:  Roberto Laureano-Melo; Anderson Luiz Bezerra da Silveira; Fernando de Azevedo Cruz Seara; Rodrigo Rodrigues da Conceição; Cláudio da Silva-Almeida; Bruno Guimarães Marinho; Fábio Fagundes da Rocha; Luís Carlos Reis; Wellington da Silva Côrtes
Journal:  Metab Brain Dis       Date:  2016-06-04       Impact factor: 3.584

4.  Discovery of Potent and Selective A2A Antagonists with Efficacy in Animal Models of Parkinson's Disease and Depression.

Authors:  Sujay Basu; Dinesh A Barawkar; Vidya Ramdas; Minakshi Naykodi; Yogesh D Shejul; Meena Patel; Sachin Thorat; Anil Panmand; K Kashinath; Rajesh Bonagiri; Vandna Prasad; Ganesh Bhat; Azfar Quraishi; Sumit Chaudhary; Amol Magdum; Ashwinkumar V Meru; Indraneel Ghosh; Ravi K Bhamidipati; Amol A Raje; Vamsi L M Madgula; Siddhartha De; Sreekanth R Rouduri; Venkata P Palle; Anita Chugh; Narayanan Hariharan; Kasim A Mookhtiar
Journal:  ACS Med Chem Lett       Date:  2017-07-05       Impact factor: 4.345

Review 5.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.

Authors:  Hai-Ying Shen; Jiang-Fan Chen
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

7.  Psychological factors in asthma.

Authors:  Ryan J Van Lieshout; Glenda Macqueen
Journal:  Allergy Asthma Clin Immunol       Date:  2008-03-15       Impact factor: 3.406

8.  FACS array profiling identifies Ecto-5' nucleotidase as a striatopallidal neuron-specific gene involved in striatal-dependent learning.

Authors:  Sabrina L Ena; Jean-François De Backer; Serge N Schiffmann; Alban de Kerchove d'Exaerde
Journal:  J Neurosci       Date:  2013-05-15       Impact factor: 6.167

9.  Interactive role of adenosine and dopamine in the opiate withdrawal syndrome.

Authors:  Luigi Stella; Vito De Novellis; Maria Redenta Vitelli; Annalisa Capuano; Filomena Mazzeo; Liberato Berrino; Francesco Rossi; Amelia Filippelli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-07-17       Impact factor: 3.000

Review 10.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.